GlaxoSmithKline turned in enough vaccine sales to lead the industry in 2017, and that was without much contribution from its newly launched shingles vaccine, Shingrix.Original Article
GlaxoSmithKline tops its peers with $7.16B in 2017 vaccine sales
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.